Objective: 1) To collect information on patient characteristics, short- and long-term clinical and patient-reported outcomes; and 2) to create an infrastructure for efficient, fast, and pragmatic randomized evaluation of new interventions. Study design: Observational, prospective cohort study, according to the 'TwiCs' design. Study population: All patients with lung cancer referred to the Department of Pulmonology or the Department of Radiotherapy of the UMC Utrecht. Main study parameters/endpoints: Clinical parameters (performance status, co-morbidity, oncological history, symptoms, imaging, technical and treatment data), clinical endpoints (toxicity, reintervention and survival), and patient-reported outcomes.
The prospective U-COLOR cohort (Utrecht COhort for Lung cancer Outcome Reporting and trial inclusion), aims to: * Gather data on natural disease progression, treatment response, disease recurrence, complications, quality of life and survival of patients with lung cancer; * Collect a patient group willing to participate in studies; * Facilitate multiple, parallel randomized controlled trials within the cohort.
Study Type
OBSERVATIONAL
Enrollment
2,000
University Medical Center Utrecht
Utrecht, Netherlands
Change in Health-related Quality of Life
Assesment of Health-related quality of life in lung cancer patients undergoing treatment
Time frame: Up to 10 years after treatment
Occurence of toxicity (adverse events)
Grade ≥3 side effects occurring during or up to 3 months after radiotherapy will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). For 'dysphagia' and 'pneumonitis' endpoints, also grade 2 toxicity will be scored.
Time frame: Up to 10 years after treatment
Readmission
Reintervention (re-irradiation, surgery, other), tube feeding requirement or treatment for local and/or distant progression.
Time frame: Up to 10 years after treatment
Survival
Date of last follow-up, date of local progression, date of distant progression, location of distant progression. Overall survival (Survival of participating patients will be recorded using the follow up questionnaires \[returned by family members\] or are derived from the Statistic Netherlands Database \[in Dutch: Centraal Bureau voor de Statistiek, CBS\] and Dutch Cancer Registry \[in Dutch: Integraal Kankercentrum Nederland, IKNL\]).
Time frame: Up to 10 years after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.